In HNSCC, exosomal PD-L1 decreases after effective therapy and rises with recurrence, and patients with active disease harbor more PD-L1+ EVs than those with no evidence of disease supporting EV-based immune monitoring [60,61]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.